Gantenerumab + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimers Disease
Conditions
Alzheimers Disease
Trial Timeline
Apr 19, 2022 → Mar 13, 2023
NCT ID
NCT05256134About Gantenerumab + Placebo
Gantenerumab + Placebo is a phase 3 stage product being developed by Roche for Alzheimers Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05256134. Target conditions include Alzheimers Disease.
What happened to similar drugs?
0 of 4 similar drugs in Alzheimers Disease were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05256134 | Phase 3 | Terminated |
| NCT03443973 | Phase 3 | Terminated |
| NCT03444870 | Phase 3 | Terminated |
| NCT02882009 | Phase 1 | Completed |
| NCT02711423 | Phase 1 | Completed |
| NCT01224106 | Phase 3 | Completed |
Competing Products
15 competing products in Alzheimers Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2814 + Lecanemab + Matching Placebo (E2814) | Eisai | Phase 2/3 | 42 |
| Gantenerumab + Solanezumab + Matching Placebo (Gantenerumab) + Matching Placebo (Solanezumab) + Gantenerumab + E2814 + Lecanemab + Matching Placebo (E2814) | Eisai | Phase 2/3 | 42 |
| Gantenerumab + Solanezumab + Matching Placebo (Gantenerumab) + Matching Placebo (Solanezumab) | Eli Lilly | Phase 2/3 | 38 |
| Remternetug + Matching Placebo (Remternetug) | Eli Lilly | Phase 2/3 | 45 |
| Remternetug (SC) + Matching Placebo (Remternetug) | Eli Lilly | Phase 2/3 | 45 |
| CNP520 50mg + CNP520 15mg | Novartis | Phase 2/3 | 30 |
| CAD106 Immunotherapy + CNP520 | Novartis | Phase 2/3 | 30 |
| Trontinemab | Roche | Phase 3 | 47 |
| RO7126209 + Placebo | Roche | Phase 1 | 29 |
| RO7126209 + Placebo | Roche | Phase 1/2 | 36 |
| Gantenerumab | Roche | Phase 2/3 | 30 |
| Trontinemab | Roche | Phase 3 | 47 |
| Semaglutide + Placebo | Novo Nordisk | Phase 3 | 40 |
| X/T + X-EC + Placebo + Lecanemab 10 mg/kg | Bristol Myers Squibb | Phase 2 | 42 |
| buntanetap/posiphen + Placebo | Annovis Bio | Phase 3 | 37 |